Files\\Communication from the Commission - § 3 references coded [ 0.85% Coverage]

Reference 1 - 0.51% Coverage

Finally, to support large-scale production of medical countermeasures, maintain and quickly guarantee access to sufficient production capacity, the Commission is setting up the EU FAB flexible manufacturing project, a network of ever-warm single and/or multi-technology production capacities for vaccine and therapeutics manufacturing in the EU. The goal is to greatly reduce the time needed between development and industrial scale-up.

Reference 2 - 0.23% Coverage

v Establish close linkages with and build on the outcomes of relevant programmes and initiatives such as IPCEI Health and EU FAB. A first step will be to devote some €120 million to a call for EU FAB in early 2022.

Reference 3 - 0.11% Coverage

The activation of EU FAB facilities to make available reserved surge manufacturing capacities;

Files\\Communication from the Commission Annex - § 1 reference coded [ 0.06% Coverage]

Reference 1 - 0.06% Coverage

• EU FAB

Files\\Press Release - § 1 reference coded [ 1.63% Coverage]

Reference 1 - 1.63% Coverage

The EU FAB facilities, a network of ever warm production capacities for vaccines and medicines manufacturing, will be set in motion to make available reserved surge manufacturing capacities, as well as emergency research and innovation plans in dialogue with Member States.

Files\\Proposal for a Council Regulation - § 3 references coded [ 0.69% Coverage]

Reference 1 - 0.10% Coverage

the activation of EU FAB facilities to make available reserved surge manufacturing capacities to ensure the delivery of the crisis-relevant medical countermeasures and raw materials;

Reference 2 - 0.35% Coverage

In such a situation, surge production and manufacturing of crisis-relevant medical countermeasures is essential and the Commission should be entrusted to activate the surge Union manufacturing capacities for crisis-relevant medical countermeasures, including ensuring resilient supply chains for the needed raw materials and ancillary supplies, under the ‘EU-FAB’. As outlined in the Communication ‘HERA Incubator: Anticipating together the threat of COVID19 variants’28 , an “EU FAB” project is a network of ‘ever-warm’, single and/or multi user, single and/or multi-technology production capacities for vaccine and medicine manufacturing at European level.

Reference 3 - 0.24% Coverage

The Commission shall have the ability and responsibility to activate the EU-FAB facilities in order to make available reserved surge manufacturing capacities to ensure the delivery of crisis-relevant medical countermeasures and raw materials, corresponding to the agreed quantities and in accordance with the timing of the EUFAB contracts. Specific procurement procedures for these agreed quantities of crisisrelevant medical countermeasures shall be conducted.